Evidence map›Paper›PMID 34609672›Full record

ArticleInternational ophthalmology2022

Ahmed glaucoma valve implantation for secondary glaucoma post-vitrectomy.

Sevgi Subasi, Nursen Yuksel, Veysel L Karabas, Busra Yilmaz Tugan, Ece Basaran

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Clinical outcomes of the PAUL Glaucoma implant for neovascular glaucoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sevgi SubasiMedical Faculty Department of Ophthalmology, Kocaeli University, İzmit, Kocaeli, Turkey. sevgiozel_5@hotmail.com.
Nursen YukselMedical Faculty Department of Ophthalmology, Kocaeli University, İzmit, Kocaeli, Turkey.
Veysel L KarabasMedical Faculty Department of Ophthalmology, Kocaeli University, İzmit, Kocaeli, Turkey.
Busra Yilmaz TuganMedical Faculty Department of Ophthalmology, Kocaeli University, İzmit, Kocaeli, Turkey.
Ece BasaranMedical Faculty Department of Ophthalmology, Kocaeli University, İzmit, Kocaeli, Turkey.
Kocaeli Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAhmed glaucoma valv (AGV) implantation is one of the successful surgical methods in secondary glaucoma that develops after pars plana vitrectomy (PPV). In our study, we aimed to evaluate the 1-year results of AGV implantation in patients with a history of PPV. STUDY

designA total of 26 patients who underwent AGV implantation after PPV were included in our retrospective study. Fourteen of 26 patients had AGV implantation due to neovascular glaucoma (NVG) and 12 of them had secondary refractory galucoma. Data of these two groups of patients were evaluated in terms of IOP reduction, number of medication use, surgical complete and qualified success, surgical failure, and complications.

resultsThe mean IOP was 29.54 ± 4.87 mmHg at the preoperative of AGV implantation and 12.88 ± 4.17 at the twelfth month visit in overal group. There was no statistically significant difference between two groups in terms of IOP in preoperative and all postoperative visits (p > 0.05). The mean intervals between PPV and AGV implantation were 67 ± 34 days in NVG and 391 ± 500 days in non-NVG group (p = 0.017). In overall group, 91.7% of patients had improvement in BCVA at the twelfth month visit. Complete and qualified surgical success rates were 75%, 83.3% in NVG group and 50%, 91.7% in non-NVG group, respectively. There was no devastating complication in both groups.

conclusionAGV implantation is a safe and effective surgical method in uncontrolled IOP elevations after PPV. While surgical success and failure rates were similar between etiologies, the time required for AGV implantation after PPV was shorter in NVG etiology.

Indexed as

GlaucomaGlaucoma Drainage ImplantsFollow-Up StudiesHumansIntraocular PressureRetrospective StudiesTreatment OutcomeVitrectomyAhmed glaucoma valvNeovascular glaucomaPars plana vitrectomySecondary glaucoma

Identifiers

PMID34609672
OpenAlexW3203947172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.